Auger radiation targeted into DNA: a therapy perspective
- 8 August 2006
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (11) , 1352-1363
- https://doi.org/10.1007/s00259-006-0187-2
Abstract
Auger electron emitters that can be targeted into DNA of tumour cells represent an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the high linear energy transfer (LET) of Auger electrons gives a high relative biological efficacy similar to that of α particles. In contrast to α radiation, however, Auger radiation is of low toxicity when decaying outside the cell nucleus, as in cytoplasm or outside cells during blood transport. The challenge for such therapies is the requirement to target a high percentage of all cancer cells. An overview of Auger radiation therapy approaches of the past decade shows several research directions and various targeting vehicles. The latter include hormones, peptides, halogenated nucleotides, oligonucleotides and internalising antibodies. Here, we will discuss the basic principles of Auger electron therapy as compared with vector-guided α and β radiation. We also review some radioprotection issues and briefly present the main advantages and disadvantages of the different targeting modalities that are under investigation.Keywords
This publication has 115 references indexed in Scilit:
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006
- The potential for gene-targeted radiation therapy of cancersTrends in Biotechnology, 2005
- Selection and Stabilization of the RNA Aptamers against the Human Immunodeficiency Virus Type-1 Nucleocapsid ProteinBiochemical and Biophysical Research Communications, 2002
- Transgenerational Effects of Preconception Paternal Contamination with55FeRadiation Research, 2001
- Cytotoxicity of 125 I-oestrogen decay in non-oestrogen receptor-expressing human breast cancer cells, MDA-231 and oestrogen receptor-expressing MCF-7 cellsInternational Journal of Radiation Biology, 2001
- Radiopharmaceuticals for Nuclear Endocrinology at the University of MichiganCancer Biotherapy & Radiopharmaceuticals, 2000
- Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitorsEuropean Journal Of Cancer, 1996
- Biodistribution of iodine-125 tyramine transforming growth factor ? antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injectionEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Contributions of nuclear medicine to the therapy of malignant tumorsZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- A microdosimetric interpretation of the radiobiological effectiveness of125I and the problem of quality factorRadiation and Environmental Biophysics, 1987